Hearing on Proposal to Withdraw Approval for the Breast Cancer Indication for Bevacizumab (Avastin) Day 2 The Food and Drug Administration (FDA) is granting a hearing to Genentech, Inc., on the Center for Drug Evaluation and Research's (CDER's) proposal to withdraw accelerated approval of the breast cancer indication for bevacizumab (Avastin). Genentech and CDER are the parties to the hearing. (Javascript is required to view Mediasite content)